Regulus Therapeutics Inc. (RGLS) News
Filter RGLS News Items
RGLS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RGLS News From Around the Web
Below are the latest news stories about REGULUS THERAPEUTICS INC that investors may wish to consider to help them evaluate RGLS as an investment opportunity.
With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big gunsKey Insights Given the large stake in the stock by institutions, Regulus Therapeutics' stock price might be vulnerable... |
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: |
Regulus: Q3 Earnings SnapshotSAN DIEGO (AP) — Regulus Therapeutics Inc. RGLS) on Thursday reported a loss of $14.1 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 21 cents. |
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2024. |
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say AnalystsIn his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable wisdom for investors: no matter the strategy, success in the stock market ultimately depends on how well you navigate the balance between risk and reward. Few corners of the stock market present a greater potential return for the risk than penny stocks, which trade at $5 or less. These ultra-low-priced equities offer an attractive entry point for investors look |
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. |
Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: |
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Regulus: Q2 Earnings SnapshotSAN DIEGO (AP) — Regulus Therapeutics Inc. RGLS) on Thursday reported a loss of $11 million in its second quarter. On a per-share basis, the San Diego-based company said it had a loss of 17 cents. |
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. |